F10 and cardiovascular disorder: For the treatment and prevention of cardiovascular diseases, such as atrial fibrillation and acute venous thromboembolism, apixaban, edoxaban, rivaroxaban, and betrixaban have been approved as direct FXa inhibitors, and these agents significantly reduce clot-associated or prothrombinase activity and the risk of stroke or systemic embolism [41,42].